The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
Advised Netomnia, a UK-based fibre operator, on its first large-scale fundraise of £123m
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
Advising SiFi Networks America Limited, which provides open access fiber-to-the-home (“FTTH”) networks across the US, on the sale of a 16.7% stake and establishing a joint venture with APG, under which APG will invest a $500m equity commitment
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
Advised Liberty Global Inc., one of the world’s leading converged telecommunication companies with operations in seven European countries, on the creation of AtlasEdge, a pan-European Edge Data Centre Joint Venture with the digital infrastructure investor Digital Colony
Advising Bruc OPT Energy Partners (“BROP”), a renewable energy JV owned by OPTrust and Mr. Juan Béjar, on the sale of a 50% stake in Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development, to funds managed by Universities Superannuation Scheme (“USS”), the largest pension scheme by assets in the UK
Advised Fluor Corporation, a global engineering, procurement and construction company and the majority investor in NuScale, a leading developer of small modular reactor nuclear technology, on the equity capital raise for NuScale
Advised ASX-listed Worley Limited on the sale of its Capital Projects Advisory business, a market leading provider of public infrastructure advisory services in Australia, New Zealand and Southeast Asia, to TSA Management (a portfolio company of Quadrant Private Equity)
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc